RecruitingNCT03740503

Genomic Investigation of Unusual Responders

Sponsor

University Health Network, Toronto

Enrollment

100 participants

Start Date

Nov 1, 2013

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Cancer Non-small Cell Lung Cancer

Summary

Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic agents in an effort to understand the fundamental genetic basis of this response. The present protocol seeks to retrospectively perform Exome, next-generation (DNA) sequencing and/or other molecular techniques on tumor samples to identify the genetic basis of a patient's exceptional response to chemotherapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is collecting tissue and genetic information from cancer patients who had an unusually good or unusually poor response to their cancer treatment, to understand why some people respond so differently than expected. **You may be eligible if...** - Your doctor considers you to have had an exceptionally good response to treatment (such as a complete or long-lasting remission) - OR your doctor considers you to have had an exceptionally poor response when a good response was expected - You are willing to provide a tissue sample and genetic information - You can give informed consent **You may NOT be eligible if...** - Your treatment response was considered typical or average - You are unable or unwilling to provide consent or a tissue sample - Your doctor does not identify you as an unusual responder Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.